And I think that the first phase given that we’re just kicking off the commercial launch with a very €“ focus on Nashville is the right way to go and is the right long-term strategy. And again, we’ll continue to look at ways that we can build out more capacity here in Nashville. And then like I said, also with the virtual training options, and as we get deeper into the launch, I think the collective learnings will allow hopefully for more of a rapid onboarding and realize too that exposing somebody’s DAXXIFY’s step one. The step two is the field salespeople need to schedule time to go into that practice, bring samples, set up a DAXXIFY day, so there’s some logistics as well that will play into this on the backend with our sales reps and why we think it’s important to add to that group.
And so we look at this less of a bottleneck and more as what we think is a very thoughtful and responsible way to onboard accounts with the goal of driving longer-term stickiness. In terms of now that we’ve got both the toxin and a filler and bundling and different things, we will of course look at ways over time to reward customers that lean in more with us. Right now, our strategy is very much giving accounts sort of a democratic way to buy and get best pricing whenever they purchase our product. But certainly over time we will look at ways to find partnerships that make sense because we do have both a toxin and a filler, we think in the near-term, having both of those will open doors for us and give us an opportunity to ask for more business, either on the toxin side or on the filler side if for example, we have strength in one of those areas, but not the other.
Operator: Douglas Tsao with H.C. Wainwright, your line is open.
Douglas Tsao: Hi, good afternoon, and thanks for taking the questions and congrats on the progress. So maybe it’s a starting point on therapeutics. Mark, should we think that the addition of Vlad Coric to the Board, is a signal of renewed interest in starting a migraine program?
Mark Foley: Yes. I wouldn’t overly read into it. I mean, we’re looking at continuing to add expertise to the Board that we think is going to be really good for our overall business. If you look at Vlad’s background and the experience that he has in, he’s an MD, so adding an MD to the Board makes a lot of sense. He comes out of clinical practice and then he’s got extensive experience in the overall pharma space with the focus on neurology. So I think he can help us think through a lot of our strategy around indication expansion, go-to-market strategy in those markets, and a variety. So I wouldn’t overly read into it. I just think we’re fortunate to have Vlad join the Board of note dermatologist. So he also will get the aesthetic side of the business. But obviously somebody with his experience and the success that he’s had in the market is going to be another important voice around the Board table, and we’re excited to have him as part of the team.
Douglas Tsao: Yes. No, I mean, I have to say, I think his experience features for itself and he is a great addition. Also on therapeutics, maybe just talk about the plan sort of rollout of in CD, obviously it’s a much more concentrated market, but it sounds like you’re still sort of going to go through a PrevU process. I guess maybe talk a little bit about how it will sort of differ from or similar as well as differ from what you’ve done in aesthetics. Thank you.
